Genomics and the Immune Landscape of Osteosarcoma

被引:42
作者
Wu, Chia-Chin [1 ]
Livingston, J. Andrew [2 ,3 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Sarcoma Med Oncol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Pediat, Houston, TX 77030 USA
来源
CURRENT ADVANCES IN THE SCIENCE OF OSTEOSARCOMA: RESEARCH PERSPECTIVES: TUMOR BIOLOGY, ORGAN MICROENVIRONMENT, POTENTIAL NEW THERAPEUTIC TARGETS, AND CANINE MODELS, 2ND EDITION | 2020年 / 1258卷
关键词
Osteosarcoma; Genomics; Next-generationsequencing (NGS); Chromothripsis; Telomere lengthening; Immune profiling; CHROMOSOMAL INSTABILITY; PD-L1; EXPRESSION; TP53; MUTATIONS; HUMAN CANCERS; DNA-DAMAGE; P53; LOSS; CELLS; TELOMERES; REPAIR; CHROMOTHRIPSIS;
D O I
10.1007/978-3-030-43085-6_2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Conventional osteosarcoma (OS) is a high-grade intraosseous malignancy with production of osteoid matrix; however, a deeper dive into the underlying genetics reveals genomic complexity and instability that result in significant tumor heterogeneity. While early karyotyping studies demonstrated aneuploidy with chromosomal complexity and structural rearrangements, further investigations have identified few recurrent genetic alterations with the exception of the tumor suppressors TP53 and RB1. More recent studies utilizing next-generation sequencing (NGS; whole-exome sequencing, WES; and whole-genome sequencing, WGS) reveal a genomic landscape predominantly characterized by somatic copy number alterations rather than point/indel mutations. Despite its genomic complexity, OS has shown variable immune infiltrate and limited immunogenicity. In the current chapter, we review the hallmarks of OS genomics across recent NGS studies and the immune profile of OS including a large institutional cohort of OS patients with recurrent and metastatic disease. Understanding the genomic and immune landscape of OS may provide opportunities for translation in both molecularly targeted therapies and novel immuno-oncology approaches.
引用
收藏
页码:21 / 36
页数:16
相关论文
共 80 条
  • [1] Signatures of mutational processes in human cancer
    Alexandrov, Ludmil B.
    Nik-Zainal, Serena
    Wedge, David C.
    Aparicio, Samuel A. J. R.
    Behjati, Sam
    Biankin, Andrew V.
    Bignell, Graham R.
    Bolli, Niccolo
    Borg, Ake
    Borresen-Dale, Anne-Lise
    Boyault, Sandrine
    Burkhardt, Birgit
    Butler, Adam P.
    Caldas, Carlos
    Davies, Helen R.
    Desmedt, Christine
    Eils, Roland
    Eyfjord, Jorunn Erla
    Foekens, John A.
    Greaves, Mel
    Hosoda, Fumie
    Hutter, Barbara
    Ilicic, Tomislav
    Imbeaud, Sandrine
    Imielinsk, Marcin
    Jaeger, Natalie
    Jones, David T. W.
    Jones, David
    Knappskog, Stian
    Kool, Marcel
    Lakhani, Sunil R.
    Lopez-Otin, Carlos
    Martin, Sancha
    Munshi, Nikhil C.
    Nakamura, Hiromi
    Northcott, Paul A.
    Pajic, Marina
    Papaemmanuil, Elli
    Paradiso, Angelo
    Pearson, John V.
    Puente, Xose S.
    Raine, Keiran
    Ramakrishna, Manasa
    Richardson, Andrea L.
    Richter, Julia
    Rosenstiel, Philip
    Schlesner, Matthias
    Schumacher, Ton N.
    Span, Paul N.
    Teague, Jon W.
    [J]. NATURE, 2013, 500 (7463) : 415 - +
  • [2] Increased genome instability and oxidative DNA damage and their association with IGF-1 levels in patients with active acromegaly
    Bayram, Fahri
    Bitgen, Nazmiye
    Donmez-Altuntas, Hamiyet
    Cakir, Ilkay
    Hamurcu, Zuhal
    Sahin, Fatma
    Simsek, Yasin
    Baskol, Gulden
    [J]. GROWTH HORMONE & IGF RESEARCH, 2014, 24 (01) : 29 - 34
  • [3] Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma
    Behjati, Sam
    Tarpey, Patrick S.
    Haase, Kerstin
    Ye, Hongtao
    Young, Matthew D.
    Alexandrov, Ludmil B.
    Farndon, Sarah J.
    Collord, Grace
    Wedge, David C.
    Martincorena, Inigo
    Cooke, Susanna L.
    Davies, Helen
    Mifsud, William
    Lidgren, Mathias
    Martin, Sancha
    Latimer, Calli
    Maddison, Mark
    Butler, Adam P.
    Teague, Jon W.
    Pillay, Nischalan
    Shlien, Adam
    McDermott, Ultan
    Futreal, P. Andrew
    Baumhoer, Daniel
    Zaikova, Olga
    Bjerkehagen, Bodil
    Myklebost, Ola
    Amary, M. Fernanda
    Tirabosco, Roberto
    Van Loo, Peter
    Stratton, Michael R.
    Flanagan, Adrienne M.
    Campbell, Peter J.
    [J]. NATURE COMMUNICATIONS, 2017, 8
  • [4] The landscape of somatic copy-number alteration across human cancers
    Beroukhim, Rameen
    Mermel, Craig H.
    Porter, Dale
    Wei, Guo
    Raychaudhuri, Soumya
    Donovan, Jerry
    Barretina, Jordi
    Boehm, Jesse S.
    Dobson, Jennifer
    Urashima, Mitsuyoshi
    Mc Henry, Kevin T.
    Pinchback, Reid M.
    Ligon, Azra H.
    Cho, Yoon-Jae
    Haery, Leila
    Greulich, Heidi
    Reich, Michael
    Winckler, Wendy
    Lawrence, Michael S.
    Weir, Barbara A.
    Tanaka, Kumiko E.
    Chiang, Derek Y.
    Bass, Adam J.
    Loo, Alice
    Hoffman, Carter
    Prensner, John
    Liefeld, Ted
    Gao, Qing
    Yecies, Derek
    Signoretti, Sabina
    Maher, Elizabeth
    Kaye, Frederic J.
    Sasaki, Hidefumi
    Tepper, Joel E.
    Fletcher, Jonathan A.
    Tabernero, Josep
    Baselga, Jose
    Tsao, Ming-Sound
    Demichelis, Francesca
    Rubin, Mark A.
    Janne, Pasi A.
    Daly, Mark J.
    Nucera, Carmelo
    Levine, Ross L.
    Ebert, Benjamin L.
    Gabriel, Stacey
    Rustgi, Anil K.
    Antonescu, Cristina R.
    Ladanyi, Marc
    Letai, Anthony
    [J]. NATURE, 2010, 463 (7283) : 899 - 905
  • [5] Prognostic factors in high-grade osteosarcoma of the extremities or trunk:: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols
    Bielack, SS
    Kempf-Bielack, B
    Delling, G
    Exner, GU
    Flege, S
    Helmke, K
    Kotz, R
    Salzer-Kuntschik, M
    Werner, M
    Winkelmann, W
    Zoubek, A
    Jürgens, H
    Winkler, K
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) : 776 - 790
  • [6] Tissue-specific mutation accumulation in human adult stem cells during life
    Blokzijl, Francis
    de Ligt, Joep
    Jager, Myrthe
    Sasselli, Valentina
    Roerink, Sophie
    Sasaki, Nobuo
    Huch, Meritxell
    Boymans, Sander
    Kuijk, Ewart
    Prins, Pjotr
    Nijman, Isaac J.
    Martincorena, Inigo
    Mokry, Michal
    Wiegerinck, Caroline L.
    Middendorp, Sabine
    Sato, Toshiro
    Schwank, Gerald
    Nieuwenhuis, Edward E. S.
    Verstegen, Monique M. A.
    van der Laan, Luc J. W.
    de Jonge, Jeroen
    IJzermans, Jan N. M.
    Vries, Robert G.
    van de Wetering, Marc
    Stratton, Michael R.
    Clevers, Hans
    Cuppen, Edwin
    van Boxtel, Ruben
    [J]. NATURE, 2016, 538 (7624) : 260 - +
  • [7] Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations
    Bousquet, M.
    Noirot, C.
    Accadbled, F.
    de Gauzy, J. Sales
    Castex, M. P.
    Brousset, P.
    Gomez-Brouchet, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (04) : 738 - 744
  • [8] Nonsense-mediated mRNA decay (NMD) mechanisms
    Brogna, Saverio
    Wen, Jikai
    [J]. NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2009, 16 (02) : 107 - 113
  • [9] Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
    Brown, Scott D.
    Warren, Rene L.
    Gibb, Ewan A.
    Martin, Spencer D.
    Spinelli, John J.
    Nelson, Brad H.
    Holt, Robert A.
    [J]. GENOME RESEARCH, 2014, 24 (05) : 743 - 750
  • [10] Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses
    Burgess, Melissa Amber
    Bolejack, Vanessa
    Van Tine, Brian Andrew
    Schuetze, Scott
    Hu, James
    D'Angelo, Sandra P.
    Attia, Steven
    Priebat, Dennis A.
    Okuno, Scott H.
    Riedel, Richard F.
    Davis, Lara Emily
    Mowa, Sujana
    Reed, Damon R.
    Butterfield, Lisa Helene
    Roszik, Jason
    Reinke, Denise K.
    Baker, Laurence H.
    Maki, Robert G.
    Patel, Shreyaskumar
    Tawbi, Hussein Abdul-Hassan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35